Studies of Neurological Paraneoplastic Syndromes

Memorial Sloan Kettering Cancer Center (MSK)

Status: Completed

Conditions: Paraneoplastic Neurologic Degenerations (PNDs)

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00587106

88-044

Details and patient eligibility

About

This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.

Full description

Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer.

Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:

• analyzing for autoantibodies in serum and cerebral spinal fluid
• analyzing for antigen specificity and for antigens in cancer tissue
• comparing PND autoantibodies with those in cancer patients but no PND
• comparing PND autoantibodies with those in PND patients but no cancer
• studying the immune performance of patients with PNDs

As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.

Enrollment: 51 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All adults are potentially eligible.

Exclusion criteria

• None.

Trial design

51 participants in 1 patient group

1

Description:

One cohort group of patient with PNDS or suspected PNDS